Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Polyclonal HIF1AN Primary Antibody for EM, ICC - ABIN151887
Birle, Hedley: Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. in Cancer research 2007
Show all 21 Pubmed References
Human Monoclonal HIF1AN Primary Antibody for ICC, IF - ABIN440718
Cockman, Lancaster, Stolze, Hewitson, McDonough, Coleman, Coles, Yu, Hay, Ley, Pugh, Oldham, Masson, Schofield, Ratcliffe: Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). in Proceedings of the National Academy of Sciences of the United States of America 2006
Show all 7 Pubmed References
Authors identified KANK3 as a new substrate for the oxygen sensor hypoxia-inducible factor 1-alpha inhibitor (HIF1AN), which hydroxylates HIF-1 (show HIF1A Antibodies)/2alpha and other ankyrin (show ANK Antibodies) repeat domain-containing proteins at asparagine residues.
MiR (show MLXIP Antibodies)-31-5p plays an important role in HS formation by inhibiting FIH (show CASR Antibodies) and regulating the HIF-1alpha (show HIF1A Antibodies) pathway.
Low FIH1 expression is associated with chemotherapy resistance in breast cancer.
data support a model in which the facial triad carboxylate Asp (show ASIP Antibodies)(201) provides both steric and polar contacts to favor O2 access to the Fe(II) only after substrate binds, leading to coupled turnover in FIH (show CASR Antibodies) and other alphaKG oxygenases.
None of the clinicopathological parameters were associated with the expressions of FIH-1 and SOCS3 (show SOCS3 Antibodies) at mRNA level.
This study provides novel clues indicating that miR (show MLXIP Antibodies)-21, miR (show MLXIP Antibodies)-31, and miR (show MLXIP Antibodies)-184 co-target FIH (show CASR Antibodies) tumor suppressor during pathogenesis in the vast majority of head and neck squamous cell carcinoma.
Results suggest that NECAB3 (show NECAB3 Antibodies), a novel Mint3 (show APBA3 Antibodies)-binding protein, activates HIF-1 (show HIF1A Antibodies) to promote normoxic glycolysis and tumorigenicity by forming a ternary complex with Mint3 (show APBA3 Antibodies) and FIH-1.
the levels of both miR (show MLXIP Antibodies)-182 and HIF1alpha (show HIF1A Antibodies) were elevated, while the expression PHD2 (show EGLN1 Antibodies) and FIH1 was downregulated in a mouse model of prostate cancer.
OTUB1 (show OTUB1 Antibodies) is a target for functional hydroxylation by FIH (show CASR Antibodies).
demonstrates that miR (show MLXIP Antibodies)-135b regulates ERalpha (show ESR1 Antibodies), AR and HIF1AN protein levels through interaction with their 3'UTR (show UTS2R Antibodies) regions, and proliferation in ERalpha (show ESR1 Antibodies)-positive BCa (show BLNK Antibodies) and AR-positive PCa (show FLVCR1 Antibodies) cells
FIH-1 has a role in disrupting the LRRK1/EGFR (show EGFR Antibodies) complex to positively regulate keratinocyte migration
miR (show MLXIP Antibodies)-31/FIH1 pathway associates with liver fibrosis, perhaps by participation in the TGF-beta (show TGFB1 Antibodies)/Smad3 (show SMAD3 Antibodies) signalling of hepatic stellate cells.
gankyrin (show PSMD10 Antibodies) binds to and sequester factor inhibiting hypoxia-inducible factor-1 (show HIF1A Antibodies) (FIH-1), which results in decreased interaction between FIH-1 and hypoxia-inducible factor-1alpha (HIF-1alpha (show HIF1A Antibodies)) and increased activity of HIF-1 (show HIF1A Antibodies) to promote VEGF (show VEGFA Antibodies) production.
Our results define a previously unknown mechanism for keratinocyte fate decisions where Notch (show NOTCH1 Antibodies) signaling potential is, in part, controlled through a miR (show MLXIP Antibodies)-31/FIH-1 nexus.
Overexpression of factor inhibiting HIF-1 enhances vessel maturation and tumor growth via platelet-derived growth factor-C (show PDGFC Antibodies) in osteosarcoma.
FIH (show CASR Antibodies) recognizes distinct molecular features within HIF-alpha1 versus ankyrin (show ANK Antibodies) repeat containing substrates Notch1 (show NOTCH1 Antibodies)/4 and Gankyrin (show PSMD10 Antibodies).
FIH1 appears to be a suppressor of oxygen-dependent genes in the kidney, operating through HIF-dependent and -independent mechanisms.
Lackin of hypoxia-inducible factor 1 alpha subunit inhibitor exhibit reduced body weight, elevated metabolic rate, hyperventilation, and improved glucose and lipid homeostasis and are resistant to high-fat-diet-induced weight gain and hepatic steatosis.
This gene encodes the alpha subunit of transcription factor hypoxia-inducible factor-1 (HIF-1), which is a heterodimer composed of an alpha and a beta subunit. HIF-1 functions as a master regulator of cellular and systemic homeostatic response to hypoxia by activating transcription of many genes, including those involved in energy metabolism, angiogenesis, apoptosis, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. HIF-1 thus plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene.
hypoxia-inducible factor 1 alpha
, hypoxia inducible factor 1 alpha
, Hypoxia-inducible factor 1 alpha
, factor inhibiting HIF-1
, factor inhibiting HIF1
, hypoxia-inducible factor 1-alpha inhibitor
, hypoxia-inducible factor asparagine hydroxylase
, peptide-aspartate beta-dioxygenase
, hypoxia-inducible factor 1, alpha subunit inhibitor